Sun Pharma Advanced Research Company Limited has informed the Exchange regarding allotment of 3,85,10,000 Warrants pursuant to Preferential Issue at its meeting held on May 19, 2026

Warrants ConvertedFund Raising View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+11.3%Reaction day

₹161.74

prior close

₹185.55

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%+10.8% vs market

Pharmaceuticals peers, median of 159sector+0.7%+10.6% vs sector

On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 10.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+0.7

15m

+0.9

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+11.3+0.4+10.8+0.7+10.6

Next day

+13.1+1.0+12.1+1.2+12.0

+11.3+2.2+9.1+1.4+9.9

+31.7+2.2+29.4+0.8+30.9

+45.8+3.9+41.9+1.9+43.9

+43.5+4.6+38.9+2.2+41.3

+30.9+3.9+27.0+2.1+28.8

15d

+27.2+3.4+23.8+1.6+25.6

+47.2+10.3+36.9+3.3+43.9

+41.1+10.8+30.3+8.7+32.4

+19.3+14.9+4.4+9.5+9.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma Advanced Research Company (SPARC) allotted 3,85,10,000 convertible warrants to Shanghvi Finance Private Limited at INR 155.80 per warrant on preferential basis. The company received INR 149.99 crore (25% of the total issue price) as upfront payment, with the balance payable upon conversion. Each warrant is convertible into one fully paid-up equity share of face value INR 1. The paid-up capital remains unchanged for now but will increase upon warrant conversion. The warrants were allotted following board approval (January 14, 2026), shareholder approval (February 9, 2026), and in-principle exchange approvals (May 8, 2026).

Likely market impact

SPARC receives INR 150 crore in immediate capital while delaying full equity dilution until warrant conversion. Shanghvi Finance, a promoter-group entity, increases its potential stake, which could be positive for the company's funding position.